Results 41 to 50 of about 949 (170)

Isolation and Pharmacological Characterisation of Pre-Synaptic Neurotoxins from Thai and Javanese Russell’s Viper (Daboia siamensis) Venoms [PDF]

Toxins
The widespread geographical distribution of Russell’s vipers (Daboia spp.) is associated with marked variations in the clinical outcomes of envenoming by species from different countries.
Mimi Lay, Wayne C. Hodgson
doaj   +2 more sources

Peripheral Arterial Thrombosis following Russell's Viper Bites [PDF]

TH Open, 2023
Envenomings by Russell's viper (Daboia russelii), a species of high medical importance in India and other Asian countries, commonly result in hemorrhage, coagulopathies, necrosis, and acute kidney injury.
Subramanian Senthilkumaran, Ketan Patel, Elanchezhian Rajan, Pradeep Vijayakumar, Stephen W. Miller, Alexandra Rucavado, Soheil Gilabadi, Medha Sonavane, Nicholas J. Richards, Jarred Williams, Harry F. Williams, Steven A. Trim, Ponniah Thirumalaikolundusubramanian, José María Gutiérrez, Sakthivel Vaiyapuri   +14 more
doaj   +2 more sources

The Relative Efficacy of Chemically Diverse Small-Molecule Enzyme-Inhibitors Against Anticoagulant Activities of African Spitting Cobra (Naja Species) Venoms [PDF]

Frontiers in Immunology, 2021
African spitting cobras are unique among cobras for their potent anticoagulant venom activity arising from strong inhibition of Factor Xa. This anticoagulant effect is exerted by venom phospholipase A2 (Group I PLA2) toxins whose activity contributes to ...
Abhinandan Chowdhury, Abhinandan Chowdhury, Matthew R. Lewin, Matthew R. Lewin, Christina N. Zdenek, Rebecca Carter, Bryan G. Fry   +6 more
doaj   +2 more sources

Differential effects of the venoms of Russell’s viper and Indian cobra on human myoblasts [PDF]

Scientific Reports
Local tissue damage following snakebite envenoming remains a poorly researched area. To develop better strategies to treat snakebites, it is critical to understand the mechanisms through which venom toxins induce envenomation effects including local ...
Husain Bin Haidar, José R. Almeida, Jarred Williams, Bokai Guo, Anne Bigot, Subramanian Senthilkumaran, Sakthivel Vaiyapuri, Ketan Patel   +7 more
doaj   +2 more sources

Varespladib: targeting the inflammatory face of atherosclerosis [PDF]

European Heart Journal, 2010
This editorial refers to ‘Randomized trial of an inhibitor of secretory phospholipase A2 on atherogenic lipoprotein subclasses in statin-treated patients with coronary heart disease’, by R.S. Rosenson et al., doi:10.1093/eurheartj/ehq374 Atherosclerosis is a complex disease and in its pathogenesis depends on the interaction between lipoproteins and ...
Benoît J. Arsenault, S. Matthijs Boekholdt, John J.P. Kastelein   +2 more
openalex   +4 more sources

High expression of PLA2G2A in fibroblasts plays a crucial role in the early progression of carotid atherosclerosis [PDF]

Journal of Translational Medicine
Background In mouse models of atherosclerosis, knockout of the PLA2G2A gene has been shown to reduce the volume of atherosclerotic plaques. Clinical trials have demonstrated the potential of using the sPLA2 inhibitor Varespladib in combination with ...
Xin Wang, Shen Li, Chen Liu, Jiawei Zhao, Gangfeng Ren, Feng Zhang, Xuyang Liu, Shuang Cao, Yuming Xu, Zongping Xia   +9 more
doaj   +2 more sources

The synergistic inhibition of atherogenesis in apoE−/− mice between pravastatin and the sPLA2 inhibitor varespladib (A-002) [PDF]

Journal of Lipid Research, 2008
Secretory phospholipase A2 (sPLA2) activity promotes foam cell formation, increases proinflammatory bioactive lipid levels, decreases HDL levels, increases atherosclerosis in transgenic mice, and is an independent marker of cardiovascular disease. The effects of the sPLA2 inhibitor A-002 (varespladib) and pravastatin as monotherapies and in combination
Zory Shaposhnik, Xuping Wang, Joaquim Trias, Heather Fraser, Aldons J. Lusis   +4 more
openalex   +6 more sources

58 Effect of Varespladib-Protected Surfactant in Cultured Rat Alveolar Macrophages Stimulated with LPS [PDF]

Archives of Disease in Childhood, 2012
Background Secretory phospholipase A2 (sPLA2) is a crucial enzyme for inflammatory response and surfactant catabolism. Acute lung injury (ALI) is a life-threating syndrome characterized by surfactant dysfunction and raised levels of sPLA2. Varespladib is a potent selective sPLA2 inhibitor that is effective in animal models of ALI.
Diana Luca, Francesca Vendittelli, Heather Fraser, Luana Gentile, Joaquim Trias, Angelo Minucci, Ettore Capoluongo   +6 more
openalex   +3 more sources

Corrigendum to "In vitro anticoagulant effects of Bungarus venoms on human plasma which are effectively neutralized by the PLA2-inhibitor varespladib" [Toxicon Volume 252, December 2024, 108178].

Toxicon
Abhinandan Chowdhury, Bryan G. Fry, S. Samuel, Ashish Bhalla, Sakthivel Vaiyapuri, Parul Bhargava, R. Carter, Matthew R. Lewin   +7 more
semanticscholar   +2 more sources

Modulation of immunity by the secreted phospholipase A2 family

Immunological Reviews, Volume 317, Issue 1, Page 42-70, August 2023., 2023
Summary Among the phospholipase A2 (PLA2) superfamily, which typically catalyzes the sn‐2 hydrolysis of phospholipids to yield fatty acids and lysophospholipids, the secreted PLA2 (sPLA2) family contains 11 isoforms in mammals. Individual sPLA2s have unique enzymatic specificity toward fatty acids and polar heads of phospholipid substrates and display ...
Makoto Murakami, Hiroyasu Sato, Yoshitaka Taketomi   +2 more
wiley   +1 more source